Bone/Mineral Metabolism

Top Story

Romosozumab increases bone mass, density at spine, hip

September 29, 2016

Postmenopausal women with osteoporosis assigned the monoclonal antibody romosozumab saw improved bone mineral density and bone mass at the lumbar spine and total hip, study data show.

Harry K. Genant, MD, professor emeritus of radiology, orthopedic surgery, medicine and epidemiology at the University of California at San Francisco, and colleagues evaluated data from postmenopausal women randomly assigned to placebo (n = 27), subcutaneous teriparatide (Forteo, Lilly) 20 µg once per day or subcutaneous romosozumab (n = 24; Amgen/UCB Pharma) 210 mg once per month to determine the effect of each agent on lumbar spine and hip volumetric BMD and bone mineral content (BMC) after 12 months.

In the Journals Plus

Revised AACE/ACE guideline urges evaluation, treatment for postmenopausal osteoporosis

September 28, 2016
All postmenopausal women aged at least 50 years should undergo an evaluation for osteoporosis risk, with therapy recommendations made based on the severity of…
FDA News

FDA: Biologics License Application accepted for romosozumab

September 27, 2016
The FDA recently accepted the Biologics License Application for review of romosozumab, according to a press release from Amgen and UCB. The monoclonal antibody…
By the Numbers

Five important news items from the American Society for Bone and Mineral Research Annual Meeting

September 26, 2016
The American Society for Bone and Mineral Research Annual Meeting, held in Atlanta earlier this month, produced a large amount of data from researchers from around the…
CME

Diabetic Retinopathy: The Importance of Early Screening, Referral, and Management

This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Diabetic eye disease is one of the most common causes of vision loss in the United States. As the rates of diabetes…
More »
Video
Meeting News Coverage

VIDEO: Promise of ‘-omics’ discussed at ASBMR

September 19, 2016
More »
Featured
ATA 2016

ATA 2016

CME

New Treatment Paradigms for Diabetic Retinopathy: Current Status and Applications for Practice

This activity is supported by an educational grant from Genentech, Inc.

Despite a number of effective treatment options, diabetic eye disease is a leading cause of vision loss in the United…
More »
In the Journals Plus

Romosozumab increases bone mass, density at spine, hip

September 29, 2016
Postmenopausal women with osteoporosis assigned the monoclonal antibody romosozumab saw improved bone mineral density and bone mass at the lumbar…

In the Journals Plus

Revised AACE/ACE guideline urges evaluation, treatment for postmenopausal osteoporosis

September 28, 2016
All postmenopausal women aged at least 50 years should undergo an evaluation for osteoporosis risk, with therapy recommendations made based on the…

FDA News

FDA: Biologics License Application accepted for romosozumab

September 27, 2016
The FDA recently accepted the Biologics License Application for review of romosozumab, according to a press release from Amgen and UCB. The…

By the Numbers

Five important news items from the American Society for Bone and Mineral Research Annual Meeting

September 26, 2016
The American Society for Bone and Mineral Research Annual Meeting, held in Atlanta earlier this month, produced a large amount of data from…

Meeting News CoverageVideo

VIDEO: Researchers encouraged by number needed to treat with abaloparatide

September 22, 2016
ATLANTA — In this video exclusive, E. Michael Lewiecki, MD, FACP, FACE, director of New Mexico Clinical Research and Osteoporosis Center in…

Meeting News Coverage

FRAME: Romosozumab reduces new vertebral fractures in postmenopausal women with osteoporosis

September 22, 2016
In postmenopausal women with osteoporosis, the monoclonal antibody romosozumab was associated with a lower risk for new vertebral fractures vs…

Meeting News CoverageVideo

VIDEO: Reduced DXA reimbursement may lead to undiagnosed osteoporosis, hip fractures

September 21, 2016
ATLANTA — In this video exclusive, E. Michael Lewiecki, MD, FACP, FACE, director of New Mexico Clinical Research and Osteoporosis Center in…

Meeting News CoverageVideo

VIDEO: Diabetic bone disease poses multiple avenues for research

September 20, 2016
ATLANTA — In this video exclusive, Clifford J. Rosen, MD, director of clinical and translational research and a senior scientist at the…

Meeting News CoverageVideo

VIDEO: Long-term oral bisphosphonate use mildly increases risk for osteonecrosis of the jaw

September 20, 2016
ATLANTA — In this video exclusive, Bo Abrahamsen, MD, PhD, professor and consultant endocrinologist at the Institute of Clinical Research…

Meeting News Coverage

Call to action seeks to address ‘crisis’ in treatment of osteoporosis

September 20, 2016
Nearly 3 dozen bone health-related organizations have issued a joint “call to action” to increase the screening, diagnosis and treatment…

More Headlines »
morganatic-roan